NovoLog for CSII approved for pediatric use

Novo Nordisk has received FDA approval for NovoLog (insulin aspart [rDNA origin] injection) for continuous subcutaneous insulin infusion (CSII) by external insulin pump in pediatric patients 4-18 years of age. This approval is supported by a clinical trial involving 298 patients that showed NovoLog CSII achieved similar levels of glycemic control and safety when compared to insulin lispro CSII.

For more information call (800) 727-6500 or visit www.novonordisk-us.com.